Abstract
Cellular immunotherapy has attracted increasing interest in genetic modification of immunologically competent cells in order to activate the effector cell after binding to predefined antigen. The chimeric immune-receptor strategy utilizes recombinant receptor molecules that are grafted on the surface of effector cells and comprise an extracellular antigen-binding domain and an intracellular signaling domain. The antigen-binding domain is a scFv (single-chain fragment of variable regions) derived from an antibody and is fused to a transmembrane moiety and an intracellular signaling domain that mediates cellular activation upon receptor crosslinking by binding of the scFv domain to antigen. This design of a chimeric receptor molecule combines the specific binding to predefined ligands with the initiation of intracellular signaling pathways for cellular activation (1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Eshhar Z., Waks T., Gross G., and Schindler D. G. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the or subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720–724.
Abken H., Hombach A., Reinhold U., and Ferrone S. (1998). Can combined T cell-and antibody-based immunotherapy outsmart tumor cells? Immunol. Today 19, 2–5.
Hombach A., Pohl C., Reinhold U., and Abken H. (1999). Grafted T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant disease. Hybridoma 18, 57–61.
Weijtens M. E., Willemsen R. A., Hart E. H., and Bolhuis R. L. (1998). A retroviral vector system’ sTITCH’ in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 5, 1195–1203.
Hombach A., Sircar R., Heuser C., Tillmann T., Diehl V., Kruis W., et al. (1998). Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signaling chains. Int. J. Mol. Med. 2, 99–103.
Hombach A., Koch D., Sircar R., Heuser C., Diehl V., Kruis W., et al. (1999). A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 6, 300–304.
Hombach A., Heuser C., Gerken M., Fischer B., Lewalter K., Diehl V., et al. (2000). T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther. 7, 1067–1075.
Sambrook J., Fritsch E. F., and Maniatis T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY.
Moritz D. and Groner B. (1995). A spacer region between the single chain antibody-and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther. 2, 539–546.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Hombach, A., Heuser, C., Abken, H. (2003). Generation, Expression, and Monitoring of Recombinant Immune Receptors for Use in Cellular Immunotherapy. In: Welschof, M., Krauss, J. (eds) Recombinant Antibodies for Cancer Therapy. Methods in Molecular Biology™, vol 207. Humana Press. https://doi.org/10.1385/1-59259-334-8:365
Download citation
DOI: https://doi.org/10.1385/1-59259-334-8:365
Publisher Name: Humana Press
Print ISBN: 978-0-89603-918-6
Online ISBN: 978-1-59259-334-7
eBook Packages: Springer Protocols